New quinolone antibiotics: a survey of the literature from 2005 to 2010

Bibliography

• Hooper DC, Rubinstein E. Quinolone antimicrobial agents. 3rd edition. ASM Press, Washington DC; 2003
   Google Scholar
• Emmerson AM, Jones AM. The quinolones: decades of development and use. J Antimicrob Chemother 2003;51(Suppl S1):13-20
   Google Scholar
• Mitscher LA. Bacterial topoisomerase inhibitors: quinolones and pyridone antibacterial agents. Chem Rev 2005;105:559-92
   PubMed Web of Science ®Google Scholar
• Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005;41(Suppl 2):S144-57
   Web of Science ®Google Scholar
• Rubinstein E. History of quinolones and their side effects. Chemotherapy 2001;47(Suppl 3):44-8
   Google Scholar
• Mugnaini C, Pasquini S, Corelli F. The 4-quinolone-3-carboxylic acid motif as a multi scaffold in medicinal chemistry. Curr Med Chem 2009;16:1746-67
   Google Scholar
• Drlica K, Malik M, Kerns RJ, Quinolone-mediated bacterial death. Antimicrob Agents Chemother 2008;52:385-92
   PubMed Web of Science ®Google Scholar
• Drlica K, Hiasa H, Kerns R, Quinolones: action and resistance updated. Curr Top Med Chem 2009;9:981-98
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao X, Malik M, Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. J Antimicrob Chemother 2010;65:520-4
   PubMed Web of Science ®Google Scholar
• Bisacchi GS, Dumas J. Recent advances in the inhibition of bacterial type II topoisomerases. Annu Rep Med Chem 2009;44:379-96
   Google Scholar
• Bradbury BJ, Pucci MJ. Recent advances in bacterial topoisomerase inhibitors. Curr Opin Pharmacol 2008;8:574-81
   PubMed Web of Science ®Google Scholar
• Tse-Dinh YC. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious disease. Infect Disord Drug Targets 2007;7:3-9
   PubMedGoogle Scholar
• Boteva AA, Krasnykh OP. The methods of synthesis, modification, and biological activity of 4-quinolones (review). Chem Heterocycl Compd 2009;45:757-85
   Google Scholar
• Zhang Q, Haemers A. Quinolone antimicrobial agents: structure-activity relationships. Pharmazie 1991;46:687-700
   Google Scholar
• Chu DTW, Fernandes PB. Structure-activity relationships of the fluoroquinolones. Antimicrob Agents Chemother 1989;33:131-5
   PubMed Web of Science ®Google Scholar
• Fujimaki K, Noumi T, Saikawa I, In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob Agents Chemother 1988;32:827-33
   PubMedGoogle Scholar
• Fung-Tomc JC, Minassian B, Kolek B, Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob Agents Chemother 2000;44:3351-6
   PubMed Web of Science ®Google Scholar
• Marshall SA, Jones RN. In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone. Antimicrob Agents Chemother 1993;37:2747-53
   PubMed Web of Science ®Google Scholar
• Anderson DL. Sitafloxacin hydrate for bacterial infections. Drugs Today 2008;44:489-501
   PubMed Web of Science ®Google Scholar
• Bertino JS, Zhang JZ. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis. Expert Opin Pharmacother 2009;10:2545-54
   PubMed Web of Science ®Google Scholar
• Xiao Y, Lu Y, Kang Z. Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers. Biopharm Drug Dispos 2008;29:167-72
   PubMed Web of Science ®Google Scholar
• Harnett SJ, Fraise AP, Andrews JM. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. J Antimicrob Chemother 2004;53:783-92
   PubMed Web of Science ®Google Scholar
• Vasiliou S, Vicente M, Castaner R. Finafloxacin hydrochloride. Drugs Future 2009;34:451-7
   Google Scholar
• Higgins PG, Stubbings W, Wisplinghoff H, Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010;54:1613-15
   PubMed Web of Science ®Google Scholar
• Daiichi. 8-Cyanoquinolonecarboxylic acid derivative. WO2005030752; 2005
   Google Scholar
• Fritsche TR, Biedenbach DJ, Jones RN. Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea. Antimicrob Agents Chemother 2009;53:1221-4
   PubMed Web of Science ®Google Scholar
• Matera MG. Pharmacologic characteristics of prulifloxacin. Pulm Pharmacol Ther 2006;19:20-9
   PubMed Web of Science ®Google Scholar
• Park HS, Kim HJ, Seol MJ, In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob Agents Chemother 2006;50:2261-4
   PubMed Web of Science ®Google Scholar
• Bhagwhat SS, Mundkur LA, Gupte SV, The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. Antimicrob Agents Chemother 2006;50:3568-79
   Google Scholar
• Yamakawa T, Mitsuyama J, Hayashi K. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother 2002;49:455-65
   PubMed Web of Science ®Google Scholar
• Arjona A. Nemonoxacin. Drugs Future 2009;34:196-203
   Web of Science ®Google Scholar
• Asahina Y, Takei M, Kimura T, Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4- substituted-1-pyrrolidinyl group as a C-1- substituent. J Med Chem 2008;51:3238-49
   PubMed Web of Science ®Google Scholar
• Fukuda Y. New approaches to overcoming bacterial resistance. Drugs Future 2009;34:127-36
   Google Scholar
• Ma Z, Lienhardt C. Towards an optimized therapy for tuberculosis? Drugs in clinical trials and pre-clinical development. Clin Chest Med 2009;30:755-68
   Google Scholar
• Hoshino K, Inoue K, Murakami Y, In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob Agents Chemother 2008;52:65-76
   PubMed Web of Science ®Google Scholar
• Jones RN, Fritsche TR, Sader HS. Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates. Antimicrob Agents Chemother 2008;52:3763-75
   Google Scholar
• Ryder NS. Discontinued drugs in 2008: anti-infectives. Expert Opin Investig Drugs 2010;19:1-21
   PubMed Web of Science ®Google Scholar
• Bogdanovich T, Esel D, Kelly LM, Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents. Antimicrob Agents Chemother 2005;45:3325-53
   Google Scholar
• Morrow BJ, He W, Amsler KM, In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother 2010;54:1955-64
   PubMed Web of Science ®Google Scholar
• Kazamori D, Suzuki H, Amago T, In vitro activity of WQ-3813 against nosocomial pathogens [abstract F1-1984]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, USA; 2009
   Google Scholar
• Suzuki H, Hayashi N, Amago T, WQ-3810, a next generation respiratory fluoroquinolone with outstanding activity against QRSP [abstract F1-2051]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 2008
   Google Scholar
• Suzuki H, Hayashi N, Amago T, WQ-3810, a next generation respiratory fluoroquinolone with outstanding activity against QRSP [abstract F1-2051]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 2008
   Google Scholar
• Hinman MM, Rosenberg TA, Balli D, Novel antibacterial class: a series of tetracyclic derivatives. J Med Chem 2006;49:4842-56
   Google Scholar
• Buurman ET, Johnson KD, Kelly RK, Different modes of action of naphthyridones in Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 2006;50:385-7
   Google Scholar
• Achaogen. Antibacterial fluoroquinolone analogs. WO2009137130; 2009
   Google Scholar
• Abu-Sheaib ES, Zahra JA, El-Abadelah MM, Heterocycles [h]-fused onto 4-oxoquinoline-3-carboxylic acid, V [1]. Synthesis and antibacterial activity of some new 2,3-disubstituted 7-oxo-7, 10-dihydropyrido[2,3-f]quinoxaline-8-carboxylic acids an esters. Z Naturforsch 2008;63b:555-63
   Google Scholar
• Al-Hiari YM, Qaisi AM, Abu Shuheil MY, Synthesis and antibacterial potency of 4-methyl-2, 7-dioxo-1,2,3,4,7,10-hexahydropyrido [2,3-f]quinoxaline-8-carboxylic acid, selected [a]-fused heterocycles and acyclic precursors. Z Naturforsch 2007;62b:1453-8
   Google Scholar
• Murphy ST, Case HL, Ellsworth E, The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents. Bioorg Med Chem Lett 2007;17:2150-5
   PubMedGoogle Scholar
• Warner-Lambert. Quinolone antibacterial agents. WO2005111030; 2005
   Google Scholar
• Warner-Lambert. Quinolone antibacterial agents. WO2005026165; 2005
   Google Scholar
• Warner-Lambert. Quinolone antibacterial agents. WO2005026145; 2005
   Google Scholar
• Warner-Lambert. Azetidinyl quinolones as antibacterial agents. WO2005026146; 2005
   Google Scholar
• Houghton TJ, Tanaka KSE, Kang T, Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis. J Med Chem 2008;51:6955-69
   PubMed Web of Science ®Google Scholar
• Zhu B, Marinelli BA, Goldschmidt R, Synthesis and antibacterial activity of 7-(1,2,3,4-tetrahydropyrrolo[1,2-a]-pyrazin-7-yl) quinolones. Bioorg Med Chem Lett 2009;19:4933-6
   Google Scholar
• AstraZeneca. Heterocyclic urea derivatives for the treatment of bacterial infections. WO2009147433; 2009
   Google Scholar
• Asahina Y, Iwase K, Iinuma F, Synthesis and antibacterial activity of 1-(2- fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin. J Med Chem 2005;48:3194-202
   Google Scholar
• Asahina Y, Araya I, Iwase K, Synthesis and antibacterial activity of the 4-quinolone-3-carboxylic acid derivatives having a trifluoromethyl group as a novel N-1 substituent. J Med Chem 2005;48:3443-6
   Google Scholar
• Efthimiadou EK, Karaliota A, Psomas G. Metal complexes of the third-generation quinolone antimicrobial drug sparfloxacin: structure and biological evaluation. J Inorg Biochem 2010;104:455-66
   PubMed Web of Science ®Google Scholar
• Skyrianou KC, Efthimiadou EK, Psycharis V, Nickel-quinolones interaction. Part 1 – Nickel(II) complexes with the antibacterial drug sparfloxacin: structure and biological properties. J Inorg Biochem 2009;103:1617-25
   PubMed Web of Science ®Google Scholar
• Skyrianou KC, Perdih F, Turel I, Nickel-quinolones interaction. Part 2 – interaction of nickel(II) with the antibacterial drug oxolinic acid. J Inorg Biochem 2010;104:161-70
   PubMed Web of Science ®Google Scholar
• Vieira LMM, de Almeida MV, Lourenço MCS, Synthesis and antitubercular activity of palladium and platinum complexes with fluoroquinolones. Eur J Med Chem 2009;44:4107-11
   PubMed Web of Science ®Google Scholar
• Pucci MJ, Thoma CL, Podos SD, In vitro and in vivo antibacterial activities of ACH-702 [abstract F1-2021]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 2008
   Google Scholar
• Thanassi JA, Cheng J, Podos SD, Dual targeting of gyrase and topoisomerase IV by ACH-702 [abstract F1-2022]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 2008
   Google Scholar
• Wang Q, Lucien E, Hashimoto A, Isothiazoloquinolones with enhanced antistaphylococcal activities against multi-drug resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions. J Med Chem 2007;50:199-210
   Google Scholar
• Kim HY, Pais G, Wiles JA, Optimization of the anti-MRSA activity of 3-aminomethylpyrrolidine-substituted isothiazoloquinolones [abstract F1-2054]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 2008
   Google Scholar
• Wiles JA, Hashimoto A, Thanassi JA, Isothiazolpyridones: synthesis, structure, and biological activity of a new class of antibacterial agents. J Med Chem 2006;49:39-42
   PubMed Web of Science ®Google Scholar
• Lenaerts AJ, Bitting C, Woolhiser L, Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo. Antimicrob Agents Chemother 2008;52:1513-15
   Google Scholar
• Li Q, Mitscher LA, Shen LL. The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors. Med Res Rev 2000;20:231-93
   PubMed Web of Science ®Google Scholar
• Hutchings KM, Tran TP, Ellsworth EL, Synthesis and antibacterial activity of the C-7 side chain of 3-aminoquinazolinediones. Bioorg Med Chem Lett 2008;18:5087-90
   PubMed Web of Science ®Google Scholar
• Huband MD, Cohen MA, Zurack M, In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. Antimicrob Agents Chemother 2007;51:1191-201
   PubMed Web of Science ®Google Scholar
• Brotz-Oesterhelt H, Brunner NA. How many modes of action should an antibiotic have? Curr Opin Pharmacol 2008;8:564-73
   PubMed Web of Science ®Google Scholar
• Bremmer JB, Ambrus JI, Samosorn S. Dual action-based approaches to antibacterial agents. Curr Med Chem 2007;14:1459-77
   Google Scholar
• Meunier B. Hybrid molecules with a dual mode of action: dream or reality? Acc Chem Res 2008;41:69-77
   PubMed Web of Science ®Google Scholar
• Zhi C, Long ZY, Manikowski A, Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors. J Med Chem 2006;49:1455-65
   PubMed Web of Science ®Google Scholar
• Butler MM, LaMarr WA, Foster KA, Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound. Antimicrob Agents Chemother 2007;51:119-27
   PubMed Web of Science ®Google Scholar
• Asahina Y, Nagae O, Sato T, AM-3005: synthesis and in vitro antibacterial activity of novel mutilin-quinolone hybrid antibacterial agent [abstract F1-2030]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 2008
   Google Scholar
• Ebisu H, Yamaguchi Y, Ueda R, AM-3005, a novel mutilin-quinolone hybrid antibiotic with potent activity against MRSA [abstract F1-2031]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 2008
   Google Scholar
• Yamaguchi Y, Ebisu H, Ueda R, AM-3005 (AM), a novel mutilin-quinolone hybrid, possesses potent inhibitory activity against protein synthesis with a type II topoisomerase inhibition [abstract F1-2032]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; 2008
   Google Scholar
• Robertson GT, Bonventre EJ, Doyle TB, In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:2313-23
   PubMed Web of Science ®Google Scholar
• Robertson GT, Bonventre EJ, Doyle TB, In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with Staphylococci and Streptococci. Antimicrob Agents Chemother 2008;52:2324-34
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Novel 6-O-substituted 15-membered 8A- and 9A-lactams. WO2010015703; 2010
   Google Scholar
• Glaxo Group Limited/Pliva. Macrolone compounds. WO2006050943; 2006
   Google Scholar
• Pliva. Carbamate linked macrolides useful for the treatment of microbial infections. WO2005108413; 2005
   Google Scholar
• Pliva. Ester linked macrolides useful for the treatment of microbial infections. WO2005108412; 2005
   Google Scholar
• Pokrovskaya V, Belakhov V, Hainrichson M, Design, synthesis, and evaluation of novel-fluoroquinolone-aminoglycoside hybrid antibiotics. J Med Chem 2009;52:2243-54
   PubMed Web of Science ®Google Scholar
• Pfizer. Antibacterial agents. US7304050; 2007
   Google Scholar
• Gordeev MF, Hackbarth C, Barbachyn MR, Novel oxazolidinone-quinolone hybrid antimicrobials. Bioorg Med Chem Lett 2003;13:4213-16
   PubMed Web of Science ®Google Scholar
• Jazayeri S, Moshafi MH, Firoozpour L, Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. Eur J Med Chem 2009;44:1205-9
   PubMed Web of Science ®Google Scholar
• Guay DR. An update on the role of nitrofurans in the management of urinary tract infections. Drugs 2001;61:353-64
   PubMed Web of Science ®Google Scholar
• Yu Z, Shi G, Sun Q, Design, synthesis and in vitro antibacterial/antifungal evaluation of novel 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7(1-piperazinyl)quinoline-3-carboxylic acid derivatives. Eur J Med Chem 2009;44:4726-33
   PubMed Web of Science ®Google Scholar
• Blom JF, Brutsch T, Barbaras D, Potent algicides based on the cyanobacterial alkaloid nostocarboline. Org Lett 2006;8:737-40
   PubMed Web of Science ®Google Scholar
• Palumed. Hybrid QA molecules wherein Q is an aminoquinoline and A is an antibiotic residue, their synthesis and their uses as antibacterial agent. WO2006024741; 2006
   Google Scholar
• Morphochem. Antibacterial active 5-chinolin derivative. WO2007042325; 2007
   Google Scholar
• Kamal A, Satanarayama M, Devaiah V, Synthesis and biological evaluation of coumarin linked fluoroquinolones, phthalimides and naphthalimides as potential DNA gyrase inhibitors. Lett Drug Design Discov 2006;3:494-502
   Google Scholar
• Zhao X, Quinn B, Kerns R, Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother 2006;58:1283-6
   Google Scholar
• German N, Wei P, Kaatz GW, Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. Eur J Med Chem 2008;43:2453-63
   PubMed Web of Science ®Google Scholar
• Merlion. Hybrid antimicrobial compounds and their use. WO2010025906; 2010
   Google Scholar
• Hennard C, Truong QC, Desnottes JF, Synthesis and activities of pyoverdin-quinolone adducts: a perspective approach to a specific therapy against Pseudomonas aeruginosa. J Med Chem 2001;44:2139-51
   PubMed Web of Science ®Google Scholar
• Diarra MS, Lavoie MC, Jacques M, Species selectivity of new siderophore-drug conjugates that use specific iron uptake for entry into bacteria. Antimicrob Agents Chemother 1996;40:2610-17
   Google Scholar
• Md-Saleh SR, Chilvers EC, Kerr KG, Synthesis of citrate-ciprofloxacin conjugates. Bioorg Med Chem Lett 2009;19:1496-98
   PubMed Web of Science ®Google Scholar
• Rivault F, Liebert C, Burger A, Synthesis of pyochelin-norfloxacin conjugates. Bioorg Med Chem Lett 2007;17:640-4
   PubMed Web of Science ®Google Scholar
• de Almeida MV, Saraiva MF, de Souza MVN, Synthesis and antitubercular activity of lipophilic moxifloxacin and gatifloxacin derivatives. Bioorg Med Chem Lett 2007;17:5661-4
   PubMed Web of Science ®Google Scholar
• Carta A, Palomba M, Paglietta G, [1,2,3]Traiazolo[4,5-h]quinolones. A new class of potent antitubercular agents against multidrug resistant Mycobacterium tuberculosis strains. Bioorg Med Chem Lett 2007;17:4791-4
   PubMed Web of Science ®Google Scholar
• Senthilkumar P, Dinakaran M, Banerjee D, Synthesis and mycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids. Bioorg Med Chem 2008;16:2258-69
   Google Scholar
• Sriram D, Senthilkumar P, Dinakaran M, Antimycobacterial activities of novel 1-(cyclopropyl/ tert-butyl/4-fluorophenyl)-1,4-dihydro-6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid. J Med Chem 2007;50:6232-9
   PubMed Web of Science ®Google Scholar
• Stella V, Borchardt R, Hageman M, Prodrugs. Springer, New York; 2007
   Google Scholar
• Shindikar AV, Viswanathan CL. Novel fluoroquinolones: design, synthesis, and in vivo activity in mice against Mycobacterium tuberculosis H37Rv. Bioorg Med Chem Lett 2005;15:1803-6
   PubMed Web of Science ®Google Scholar
• Renau TE, Sanchez JP, Gage JW, Structure-activity relationships of the quinolone antibacterials against Mycobacteria: effect of structural changes at N-1 and C-7. J Med Chem 1996;39:729-35
   PubMed Web of Science ®Google Scholar
• Sriram D, Yogeeswari P, Reddy SP. Synthesis of pyrazinamide Mannich bases and its antitubercular properties. Bioorg Med Chem Lett 2006;16:2113-16
   Google Scholar
• Imramovsky A, Polanc S, Vinsova J, A new modification of anti-tubercular active molecules. Bioorg Med Chem 2007;15:2551-9
   PubMed Web of Science ®Google Scholar
• Sriram D, Yogeeswari P, Madhu K. Synthesis and in vitro antimycobacterial activity of isonicotinoyl hydrazones. Bioorg Med Chem Lett 2005;15:4502-5
   PubMed Web of Science ®Google Scholar
• Sriram D, Aubry A, Yogeeswari P, Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. Bioorg Med Chem Lett 2006;16:2982-5
   PubMed Web of Science ®Google Scholar
• Sriram D, Yogeeswari P, Devakaram RV. Synthesis, in vitro and in vivo antimycobacterial activities of diclofenac acid hydroazones and amide. Bioorg Med Chem 2006;14:3113-18
   PubMed Web of Science ®Google Scholar
• Zhao G, Miller MJ, Franzblua S, Synthesis and studies of quinolone-cephalosporins as potential anti-tuberculosis agents. Bioorg Med Chem Lett 2006;16:5534-7
   PubMed Web of Science ®Google Scholar
• Zhao YL, Chen YL, Sheu JY, Synthesis and antimycobacterial evaluation of certain quinolone derivatives. Bioorg Med Chem 2005;13:3921-6
   PubMed Web of Science ®Google Scholar
• van den Boogaard J, Kibiki GS, Kisanga ER. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009;53:849-62
   PubMed Web of Science ®Google Scholar
• Gutierrez-Lugo MT, Bewley CA. Natural products, small molecules, and genetics in tuberculosis drug development. J Med Chem 2008;51:2606-12
   Google Scholar
• Sriram D, Banerjee D, Yogeeswari P. Efavirenz mannich bases: Synthesis, anti-HIV and antitubercular activities. J Enzyme Inhib Med Chem 2009;24:1-5
   PubMed Web of Science ®Google Scholar
• Sriram D, Yogeeswari P, Gopal G. Synthesis, anti-HIV and antitubercular activities of lamivudine prodrugs. Eur J Med Chem 2005;40:1373-6
   PubMed Web of Science ®Google Scholar
• Sriram D, Yogeeswari P, Senchani G, Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase. Bioorg Med Chem Lett 2007;17:2372-5
   PubMed Web of Science ®Google Scholar
• Laponogov I, Sohi MK, Veselkov DA, Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol 2009;16:667-9
   PubMed Web of Science ®Google Scholar
• German N, Malik M, Rosen JD, Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2, 4-diones. Antimicrob Agents Chemother 2008;52:3915-21
   Google Scholar
• Malik M, Hoatam G, Chayda K, Novel approach for comparing the abilities of quinolones to restrict the emergence of resistant mutants during quinolone exposure. Antimicrob Agents Chemother 2010;54:149-56
   PubMed Web of Science ®Google Scholar
• Frothingham R. Glucose homeostatis abnormalities associated with use of gatifloxacin. Clin Infect Dis 2005;41:1269-76
   PubMed Web of Science ®Google Scholar
• Aspinall SL, Good CB, Jiang R, Severe Dysglycemica with the fluoroquinolones: a class effect? Clin Infect Dis 2009;49:402-8
   PubMed Web of Science ®Google Scholar